July 30, 2007Journal of Clinical Oncology

Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval

View Full Paper

Ask AI

Bookmark

Population

Oncology patients receiving molecularly targeted agents

Design

Review

Authors

ESElizabeth L. StrevelTrillium Health Centre DIDouglas IngBrigham and Women's Hospital LSLillian L. SiuNew Mexico State University

Discussion

Member takes

Implication

Clinicians should monitor QT intervals with targeted oncology agents; leaves open optimal prospective strategies.

Structured PICO

Population

Oncology patients receiving molecularly targeted agents

Intervention

Molecularly targeted oncology therapeutics (including histone deacetylase inhibitors, multitargeted tyrosine kinase inhibitors, vascular disruption agents, farnesyl protein transferase inhibitors, Src/Abl kinase inhibitors, and protein kinase C inhibitors)

Outcome

QT interval prolongationsafety

This review highlights the risk of QT prolongation associated with novel molecularly targeted oncology therapies and discusses guidelines for monitoring this toxicity during drug development.

Cite This Study

Strevel et al. (2007) studied this question.

synapsesocial.com/papers/6a6fbd21f44fa9f079dd3868 https://doi.org/10.1200/jco.2006.09.6925

View Full Paper

Ask AI

Bookmark

Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider